CRISPR RNAs trigger innate immune responses in human cells by Kim, Sojung et al.
CRISPR RNAs trigger innate immune responses
in human cells
Sojung Kim,1,6 Taeyoung Koo,1,2,6 Hyeon-Gun Jee,3,6 Hee-Yeon Cho,1 Gyeorae Lee,1,2
Dong-Gyun Lim,3 Hyoung Shik Shin,4 and Jin-Soo Kim1,2,5
1Center for Genome Engineering, Institute for Basic Science, Seoul 08826, South Korea; 2Department of Basic Science, University
of Science & Technology, Daejeon 34113, South Korea; 3Center for Chronic Diseases, Research Institute, National Medical Center,
Seoul 04564, South Korea; 4Research Center for Infectious Diseases, Research Institute, NationalMedical Center, Seoul 04564, South
Korea; 5Department of Chemistry, Seoul National University, Seoul 08826, South Korea
Here, we report that CRISPR guide RNAs (gRNAs) with a 5′-triphosphate group (5′-ppp gRNAs) produced via in vitro tran-
scription trigger RNA-sensing innate immune responses in human and murine cells, leading to cytotoxicity. 5′-ppp gRNAs
in the cytosol are recognized by DDX58, which in turn activates type I interferon responses, causing up to ∼80% cell death.
We show that the triphosphate group can be removed by a phosphatase in vitro and that the resulting 5′-hydroxyl gRNAs in
complex with Cas9 or Cpf1 avoid innate immune responses and can achieve targeted mutagenesis at a frequency of 95% in
primary human CD4+ T cells. These results are in line with previous findings that chemically synthesized sgRNAs with a 5′-
hydroxyl group aremuchmore efficient than in vitro–transcribed (IVT) sgRNAs in human and other mammalian cells. The
phosphatase treatment of IVT sgRNAs is a cost-effective method for making highly active sgRNAs, avoiding innate immune
responses in human cells.
[Supplemental material is available for this article.]
Clustered, regularly interspaced, short palindromic repeat
(CRISPR)-CRISPR associated (Cas) nucleases, which function as
an adaptive immune system in bacteria and archaea, have been re-
purposed for targeted genome editing in various cells and organ-
isms (Cho et al. 2013a; Kim and Kim 2014). The Cas9 nuclease,
the protein component in a type II CRISPR-Cas system, is com-
plexed with two small RNAs termed a target-specific CRISPR RNA
(crRNA) (∼40 nucleotides [nt] in length) and a target-independent
trans-activating crRNA (tracrRNA) (∼86-nt) to form active RNA-
guided endonucleases (Deltcheva et al. 2011; Jinek et al. 2012),
which cleaveDNA in a targetedmanner, leading to site-specific ge-
nome modifications. The essential parts of the crRNA and
tracrRNA are usually combined to generate a ∼100-nt single guide
RNA (sgRNA). Cpf1 is another RNA-guided programmable nucle-
ase, which is derived from a class 2 type V CRISPR-Cas system
(Zetsche et al. 2015). Unlike Cas9, Cpf1 requires only a single 42-
nt crRNA to cleave target DNA.
For successful CRISPR-mediated genome editing, efficient
delivery or high level expression of Cas9 or Cpf1 and a guide
RNA (gRNA) is essential. Plasmids encoding Cas9 and a gRNA or
in vitro–transcribed Cas9 mRNA and a gRNA can be codelivered
into cells. As an alternative to these methods, preassembled Cas9
or Cpf1 ribonucleoproteins (RNPs), composed of the purified
Cas9 or Cpf1 protein and a gRNA, can be also delivered into cells
via microinjection (Cho et al. 2013b; Sung et al. 2014), electropo-
ration (Kim et al. 2014, 2016; Hur et al. 2016), cationic lipid-medi-
ated transfection (Zuris et al. 2015), or protein transduction
(Ramakrishna et al. 2014). RNPs cut target DNA immediately and
are turned over rapidly in cells, which can alleviate off-target ef-
fects (Kim et al. 2014) and reduce mosaicism in whole organisms
(Woo et al. 2015). Unlike plasmid transfection, RNP delivery is
not associated with any risk of foreign DNA integration into the
host genome (Kim et al. 2014) and cannot trigger cyclic GMP-
AMP synthase (cGAS) activation, an innate immune system in
mammalian cells that protects against foreign DNA (Sun et al.
2013). This advantage of RNP delivery over plasmid transfection
has made Cas9, Cpf1, and Base Editor RNPs broadly useful for bio-
medical research and biotechnology (Woo et al. 2015; Dever et al.
2016; Kim et al. 2017a,c; Liang et al. 2017).
gRNAs in RNP complexes are typically transcribed in vitro us-
ing phage RNA polymerases such as T7 and SP6 polymerases.
These in vitro–transcribed (IVT) gRNAs contain a triphosphate
group at the 5′ terminus, which can induce a type I interferon-me-
diated immune response in various cell types (Kim et al. 2004;
Pichlmair et al. 2006). The nascent 5′-triphosphate moiety in
such an RNA molecule is recognized as part of a non-self RNA de-
rived from viral infection. Immune sensing of non-self nucleic ac-
ids by innate immune systems leads to the induction of the type I
interferons (IFNs), which in turn activate genes that encode antivi-
ral effector proteins such as DDX58 (DExD/H-box helicase 58, also
known as RIG-I), OAS2 (2′-5′-oligoadenylate synthetase), and PKR
(dsRNA-dependent protein kinase) (Schlee and Hartmann 2016).
Here, we investigate whether the 5′-triphosphate moiety in
IVT gRNAs indeed triggers the RNA-sensing innate immune re-
sponse in human cells, leading to cell death, and show how to
avoid this problem.
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Results
Activation of type I interferon responses
by 5′-triphosphate gRNA
We first tested whether IVT gRNAs (dual RNA [crRNA plus
tracrRNA] or sgRNA) could activate innate immune responses in
cultured human cells. HBB gene-specific gRNAs were synthesized
using T7 polymerase, complexed with the recombinant Streptococ-
cus pyogenes Cas9 protein expressed in and purified from Escheri-
chia coli and transfected into HeLa cells via lipofection (Fig. 1A).
The expression of IFNB1, a hallmark of the type I IFN pathway, was
evaluated by quantitative PCR and ELISA 24 h after transfection.
Figure 1. Induction of type I interferon-mediated innate immune responses in HeLa cells by in vitro–transcribed gRNA containing 5′-triphosphate. (A)
Schematic representation of gRNA 5′ ends, which vary according to the gRNA preparationmethod. gRNA sequences complementary to theHBB-target site
are shown in bold. (B,D,E) Relative IFNB1 (B), DDX58 (D), and OAS2 (E) mRNA levels 24 h after transfection. Error bars, SEM; n = 3. (C) IFNB1 levels were
measured by ELISA. Error bars, SEM; n = 3. (N.D.) None detected. (F) Cell viabilities after RNP transfection were determined by WST-1 assays. Error bars,
SEM; n = 2. Statistical significances between the differentmeasurements were calculated using one-way ANOVA. (∗∗∗) P < 0.001, (∗∗∗∗) P < 0.0001. (G) Indel
frequencies induced by the HBB-targeting Cas9 RNP were measured by targeted deep sequencing. Error bars, SEM; n = 3. Statistical significances were cal-
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The Cas9 RNP up-regulated IFNB1mRNA
levels by∼1000-fold andprotein levels by
∼200-fold (Fig. 1B,C). The Cas9 protein
alone did not activate the IFN pathway,
whereas 5′-triphosphorylated (5′-ppp)
gRNAs alone activated the expression of
IFNB1. In sharp contrast, transfection of
5′-hydroxylated (5′-OH) gRNAs, prepared
by chemical synthesis or by treatment of
IVT gRNAs with calf intestinal phospha-
tase (CIP), caused no significant differ-
ence in IFNB1 expression compared to
that of untreated negative controls. IFN-
stimulated DDX58 and OAS2 genes were
also up-regulated by 5′-ppp gRNAs but
not by 5′-OH gRNAs (Fig. 1D,E). Consis-
tent with these results, cytotoxicity,
caused by the type I IFNpathway,was ob-
served with 5′-ppp sgRNAs but not with
5′-OH gRNAs (Fig. 1F). Thus, >80% of
cells were killed by 5′-ppp sgRNAs. Dual
RNAs containing the triphosphate group
were also cytotoxic, killing up to 60% of
transfected cells.
Next, we measured HBB gene edit-
ing efficiencies in human cells transfect-
ed with 5′-ppp gRNAs or 5′-OH gRNAs
(Fig. 1G). Both 5′-OH gRNAs and 5′-ppp
gRNAs were equally efficient in HeLa
cells, demonstrating that the triphos-
phate moiety at the 5′-end of sgRNAs
does not affect DNA cleavage activity in
human cells and suggesting that indels
were formed before massive cell death.
Note also that 5′-ppp gRNA transfection
triggers production and secretion of in-
terferon proteins in the media, which
then bind to ubiquitously expressed re-
ceptors even in untransfected cells, lead-
ing to cell death.
We further investigated whether 5′-
ppp-gRNAs trigger RNA-sensing immune
responses in primary mouse embryonic
fibroblast (MEF) cells (Supplemental Fig. S1A). The Ifnb1 and
IFN-stimulated genes Ddx58 and Oas2 were up-regulated in MEF
cells transfected with 5′-ppp-sgRNAs generated via in vitro tran-
scription but not in those transfected with 5′-OH-gRNAs prepared
by chemical synthesis or CIP treatment of IVT sgRNAs (Supple-
mental Fig. S1B–D). There was no difference in gene editing effi-
ciencies between 5′-ppp-sgRNA and 5′-OH-sgRNA cotransfected
with the Cas9 protein (Supplemental Fig. S1E).
RNA-sensing immune response to CRISPR-RNA via DDX58
Cytosolic 5′-triphosphorylated RNAs, the main ligand for the
DDX58 receptor, can function as an indicator of viral infection
(Pichlmair et al. 2006; Rehwinkel et al. 2010). Hence, we hypoth-
esized that DDX58 might be involved as the immune sensor re-
sponsible for detection of IVT gRNAs. To verify this, we first
generatedDDX58 knockout (KO) cell lines using aDDX58-specific
sgRNA and Cas9 (Fig. 2A). We chose two KO clones with out-of-
frame indel mutations. mRNA levels of IFNB1, DDX58, and OAS2
were not changed in these DDX58 KO cells transfected with 5′-
ppp-gRNAs (Fig. 2B–D). Furthermore, IFN-mediated cytotoxicity
associated with 5′-ppp-gRNAs was not detectably induced in these
cells (Fig. 2E), suggesting that DDX58 is responsible for the innate
immune response to IVT gRNAs with the 5′ triphosphate moiety.
Type I interferon response induced by crRNA in Cpf1 RNPs
Next, we investigated whether Cpf1 crRNAs can also activate in-
nate immune responses in human cells. We prepared a DNMT1-
specific Acidaminococcus sp. Cpf1 (AsCpf1) crRNA via chemical
synthesis or in vitro transcription using T7 polymerase (Fig. 3A).
IFNB1, DDX58, and OAS2 mRNA levels were up-regulated by the
5′-ppp crRNA but not by the 5′-OH crRNA prepared by chemical
synthesis or by treatment of the in vitro transcript with CIP (Fig.
3B–D). Activation of these IFN-mediated immune responses by
the 5′-ppp crRNA was abrogated in DDX58 KO cells (Fig. 3E–G).
Mutation frequencies associated with treatment with RNPs con-
taining the 5′-ppp crRNA or the 5′-OH crRNA were comparable,
Figure 2. The type I interferon-mediated immune response triggered by gRNA is associated with
DDX58. (A) Genotypes of DDX58 knockout (KO) HeLa cell lines. DDX58 KO clones #1 and #2 have ho-
mozygous out-of-frame mutations at the DDX58 locus. The target sequence complementary to the
sgRNA used for mutagenesis is underlined and the PAM sequence is shown in red. (B–D) Relative
IFNB1 (B), DDX58 (C), andOAS2 (D) mRNA levels in wild-type (WT) and DDX58 KO cell lines at 24 h after
transfection. Error bars, SEM; n = 3. (E) WT and DDX58 KO cell viabilities after RNP transfection were de-
termined by WST-1 assays. Error bars, SEM; n = 3. Statistical significances among the different measure-
ments were calculated using one-way ANOVA. (∗∗) P < 0.01, (∗∗∗∗) P < 0.0001.
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showing that the cleavage activity of Cpf1 was not affected by the
5′-triphosphate group of the crRNA (Fig. 3H).
Cytotoxicity induced by 5′-ppp sgRNAs in primary human T cells
Genome editing in primary human T cells has been tested in
clinics for treating cancer and human immunodeficiency virus
type 1 (HIV-1) infection.We investigated whether 5′-triphosphate
sgRNAs trigger innate immune responses in primary human T
cells, causing cytotoxicity. We isolated primary CD4+ T cells
fromhealthy volunteers (n = 3) and transfected aCas9 RNP specific
to theCCR5 gene, which encodes an essential coreceptor of HIV-1,
into these cells via electroporation. We measured adenosine tri-
phosphate (ATP) levels to monitor cell viability and found that
the 5′-ppp gRNA treatment significantly reduced cell viability
(∗P < 0.05, ∗∗P < 0.01), whereas 5′-OH-sgRNA did not cause cyto-
toxicity (Fig. 4A). Furthermore, 5′-ppp gRNA-treated cells failed
to divide after 7 d post-electroporation, whereas cells transfected
with CIP-treated 5′-OH sgRNA in complex with the Cas9 protein
were successfully expanded (Fig. 4B).
Figure 3. RNA-sensing immune responses activated by the AsCpf1-associated crRNA. (A) Schematics ofDNMT1-targeting crRNAs, which vary according
to their preparation methods. crRNA sequences complementary to the DNMT1-target site are shown in bold. (B–D) Relative IFNB1 (B), DDX58 (C), and
OAS2 (D) mRNA levels at 24 h after transfection. Error bars, SEM; n = 3. (E–G) Relative IFNB1 (E), DDX58 (F ), and OAS2 (G) mRNA levels in WT and
DDX58 KO HeLa cell lines at 24 h post-transfection. Error bars, SEM; n = 3. (H) Indel frequencies induced by the DNMT1-targeting AsCpf1 RNP were mea-
sured using next-generation sequencing (NGS). Statistical significances were calculated by t-test. (n.s.) Not significant, (Syn) chemically synthesized crRNA,
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We next investigated whether the cytotoxicity of 5′-ppp
sgRNA in primary CD4+ T cells was caused by RNA-sensing innate
immune responses. As expected, OAS2 and DDX58 mRNA levels
were up-regulated by the 5′-triphophate sgRNA (∗∗P < 0.01) (Fig.
4C,D). The IFNB1 protein was also detected at day 3 post-electro-
poration (Fig. 4E). The 5′-OH sgRNA did not induce any detectable
immune responses, compared to the mock control.
Highly efficient CCR5 knockout in human T cells using
5′-OH sgRNA
We next measured mutation frequencies in primary T cells using
targeted deep sequencing. Removal of the 5′-triphosphate moiety
from the sgRNA enhancedmutation efficiencies at theCCR5 target
site in T cells. Thus, the 5′-OH sgRNA induced indels with a fre-
quency of 94 ± 0.4% and 92 ± 0.8% at day 3 and 7 post-electropo-
ration, respectively, whereas the 5′-ppp sgRNA inducled indels
with a frequency of 87 ± 1% and 80 ± 1% (∗∗P < 0.01) (Fig. 5A).
Importantly, 5′-OH sgRNA-treated cells remained mutated at the
CCR5 locus with a frequency of 95 ± 1% at day 25 post-treatment
(Fig. 5B).
To confirm the removal of theCCR5
protein from the surface of CD4+ T cells
as a result of CRISPR gene editing, we per-
formed flow cytometry. At day 7 post-
electroporation, 96% of cells (both
mock-treated and Cas9 RNP-treated)
were CD4 positive (Fig. 5C; Supplemen-
tal Fig. S2). Among these CD4+ T cells,
only 3.7% of cells treated with the Cas9
RNP were CCR5-positive, whereas
24.4% of mock-treated cells were CCR5-
positive, showing an 85% reduction in
the fraction of CCR5-positive cells upon
Cas9 RNP treatment (Fig. 5D; Supple-
mental Fig. S2).
Discussion
The delivery of CRISPR RNP complexes
that consist of Cas9 or Cpf1 protein and
guide RNA into mammalian (Kim et al.
2014, 2016; Hur et al. 2016) and plant
cells (Woo et al. 2015) and animal (Cho
et al. 2013b; Sung et al. 2014) andhuman
embryos (Ma et al. 2017) has been dem-
onstrated as a promising approach for
highly efficient and precise genome edit-
ing. CRISPR RNPs have been successfully
delivered into retinal pigment epitheli-
um cells (Kim et al. 2017b), neuronal
cells (Staahl et al. 2017), and hair cells
(Zuris et al. 2015) in mice, illustrating
the broad potential for clinical applica-
tions. To prepare gRNAs for RNPdelivery,
in vitro transcription using phage RNA
polymerases, such as T7 and SP6 poly-
merases, is the most accessible method
because it is easier and more affordable
than chemical synthesis for obtaining
large amounts of RNA. In particular, the
yield of ∼100-nt sgRNAs from chemical
synthesis is very low (Hendel et al. 2015), and thus preparation
of sgRNAs in amounts sufficient for transfecting 107∼109 cells by
this method can be cost-prohibitive. However, in vitro transcrip-
tion using phage RNA polymerases generates a triphosphate moi-
ety at the 5′ end of the gRNA, and the resulting 5′-triphosphate
single-stranded RNA (ssRNA) activates type I interferon-mediated
immune responses in cells. Cytosolic ssRNAs bearing 5′-triphos-
phates are recognized by the DDX58 receptor (Pichlmair et al.
2006; Rehwinkel et al. 2010), but the preference of DDX58 for
ssRNA ligands varies according to their concentration, sequence,
length, conformation, and the level of shielding by proteins
(Schlee and Hartmann 2016), and thus the minimal requirement
of a biologically relevant ssRNA ligand for DDX58 activity has re-
mained unclear. Here, we demonstrated that in vitro–transcribed
gRNAs in CRISPR-Cas9 or Cpf1 RNPs indeed trigger RNA-sensing
innate immune responses and result in cell death, which can be
prevented by removal of the 5′-triphosphate group from the gRNA.
Human T cells can be gene-edited using CRISPR systems or
other programmable nucleases for the treatment of various diseas-
es, including cancer and acquired immune deficiency syndrome
(AIDS). For example, a naturally occurring deletion in the CCR5
Figure 4. 5′-triphosphate induces RNA-sensing immune responses in human CD4+ T cells. A CCR5-tar-
geting Cas9 RNP was delivered into primary CD4+ T cells using a MaxCyte electroporation system. (A)
Cell viabilities at 3 and 7 d post-electroporation were determined by relative ATP level. (B) Live cell num-
bers fromday 0 to 8were counted after RNP delivery. RelativeOAS2 (C) andDDX58 (D) mRNA levels were
determined by real-time PCR 3 d post-electroporation. (E) IFNB1 protein levels in the supernatant were
measured by ELISA. Error bars, SEM; n = 3. Statistical significances were calculated by t-test. (∗) P < 0.05,
(∗∗) P < 0.01, (n.s.) not significant.
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gene encoding an essential coreceptor of HIV confers resistance to
HIV infection, providing the basis of cell therapy against HIV in-
fection (Hendel et al. 2015; Hultquist et al. 2016; Xu et al. 2017).
Here, we showed that delivery of RNP complexes containing
gRNAs lacking the 5′-triphosphate rescued human CD4+ primary
T cells from RNA-sensing innate immune responses, leading to ef-
ficient disruption of theCCR5 gene. Application of this strategy of-
fers great promise for targeted cell therapy using CRISPR-Cas9,
Cpf1, and Base Editor RNP complexes.
Methods
Preparation of recombinant Cas9 protein, Cpf1 protein,
and guide RNA
Recombinant Cas9 protein was purchased from ToolGen.
Recombinant Cpf1 protein was prepared as described previously
(Hur et al. 2016). Cas9 crRNAs, tracrRNAs, and sgRNAs and Cpf1
crRNAs were synthesized by in vitro transcription using T7 RNA
polymerase and a template oligonucleotide (Supplemental Table
S1) as described previously (Kim et al. 2014, 2016). CIP (New
England BioLabs) was used to remove the 5′-triphosphate from
gRNAs as follows: 10 µg of in vitro–transcribed RNA was treated
with 250 units of CIP for 3 h at 37°C in the presence of 100 units
of RNase inhibitor (New England BioLabs). Following CIP treat-
ment, the RNA was cleaned up using a miRNeasy Mini kit
(Qiagen). Chemically synthesized RNAs, which were purified us-
ing high-performance liquid chromatography (HPLC), were pur-
chased from Integrated DNA Technologies (IDT).
Cell culture and transfection
HeLa (ATCC,CCL-2) cells weremaintained inDulbecco’sModified
Eagle’s Medium (DMEM) supplemented with 100 units/mL peni-
cillin, 100 µg/mL streptomycin, 0.1mMnonessential amino acids,
and 10% fetal bovine serum (FBS). Mouse embryonic fibroblast
cells were grown in DMEM with 20% fetal bovine serum. HeLa
cells and MEF cells were transfected with 100 nM of purified
Cas9 protein or Cpf1 protein and 300 nM of gRNA using
Lipofectamine 2000 reagent (Invitrogen), as described in Zuris
et al. (2015).
Isolation of primary human CD4+ T cells
Peripheral blood was collected from healthy donors at the
National Medical Center of Korea after informed consent with
Institutional ReviewBoard approval. Peripheral bloodmononucle-
ar cells (PBMCs) were isolated by density gradient centrifugation
using Ficoll-Paque solution (GE Healthcare). Using a magnetic ac-
tivated cell sorting (MACS) CD4+ T cell isolation kit (Miltenyi
Biotec), CD4+ T cells were purified by negative selection. Isolated
CD4+ T cells were cultured in RPMI 1640 medium supplemented
with 2 mM glutamine, 1% (v/v) nonessential amino acids, 1%
(v/v) sodium pyruvate, 1% (v/v) HEPES, penicillin (50 U/mL),
streptomycin (50 µg/mL), and 10% (v/v) FBS (medium and culture
supplements from Invitrogen). Within 2 h of isolation, CD4+ T
cells were activated with CD3/CD28 Dynabeads (Thermo Fisher
Scientific). The CD3/CD28 beads were magnetically removed 72
h after activation, before delivery of RNPs for CCR5 knockout.
For long-term expansion of CD4+ T cells, CD3/CD28 Dynabeads
were added at 1:1 ratio (cell to bead) again at day 8 post-electropo-
ration (day 11 post-initial activation) (Levine et al. 1997).
RNP delivery into primary human CD4+ T cells
RNPs were delivered into T cells via electroporation. Bead-free acti-
vated CD4+ T cells were mixed with purified Cas9 protein and
sgRNA complexes in MaxCyte buffer and transferred into an OC-
100 processing assembly, followed by electroporation using a
MaxCyte-STX transfection system (MaxCyte Systems) according
to the manufacturer’s instructions. After electroporation, cells
were seeded on 96-well plates with 20 units/mL of recombinant
human IL2.
Targeted deep sequencing for mutation detection
Genomic DNA was harvested with a DNeasy Blood & Tissue kit
(Qiagen) after RNP transfection. The target regions were PCR-am-
plified using appropriate primer sets (Supplemental Table S1) for
next-generation sequencing library construction. TruSeq HT
Dual Index primers were used for labeling each sample. The result-
ing libraries were subjected to paired-end read sequencing using
MiSeq (Illumina).
Measurement of relative mRNA levels by quantitative PCR
Transfected cells were lysed and mRNAwas purified either 24 h or
3 d after transfection using a NucleoSpin RNA kit (MACHEREY-
NAGEL). cDNAs were synthesized by reverse transcription using
a miScript II RT kit (Qiagen) and quantified by qPCR using the
primers listed in Supplemental Table S1. The qPCR in primary
Figure 5. Removing the 5′-triphosphate moiety from gRNA improves
CCR5 editing efficiency in primary human CD4+ T cells. (A) Indel frequen-
cies at the CCR5 locus were calculated by targeted deep sequencing on day
3 and day 7 post-treatment. (B) Indel frequencies at the CCR5 locus were
calculated by targeted deep sequencing on day 25 post-treatment. The
percentages of cells positive for surface CD4 (C) and CCR5 protein (D)
were determined by flow cytometry. Error bars, SEM; n = 3. Statistical sig-
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humanCD4+ T cells was performed using TaqMan gene expression
assays (Thermo Fisher Scientific) with the following primers:
DDX58 (Hs01061436_m1), OAS2 (Hs00942643_m1), 18SrRNA
(Hs03928990_g1).
ELISA
The amount of IFNB1 secreted into the growthmediumwas deter-
mined using a Human IFN beta ELISA kit (PBL Assay Science). The
medium from RNP-transfected cells was collected at either 24 h or
3 d post-transfection. The IFNB1 concentration was measured ac-
cording to the manufacturer’s protocol.
Cell viability measurements
In the case of HeLa cells, 5 × 103 of either wild-type or DDX58 KO
cells were plated in 96-well plates 1 d before RNP transfection. At
day 3 after transfection, cell viability was determined by a WST-1
assay (Roche) according to the manufacturer’s protocol. In the
case of primary CD4+ T cells, they were plated in 96-well plates
after electroporation to deliver RNPs. At day 3 and 7 after electro-
poration, the ATP level in the supernatants, a measure of cell via-
bility, was determined using theCellTiter-Glo substrate (Promega).
Data access
The deep sequencing data from this study have been submitted to
theNCBI Sequence Read Archive (SRA; https://www.ncbi.nlm.nih.
gov/sra) under accession numbers SRP121089 and SRP129873.
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